BRISTOL-MYERS SQUIBB CO (BRM.DE) Fundamental Analysis & Valuation
FRA:BRM • US1101221083
Current stock price
50.62 EUR
+0.43 (+0.86%)
Last:
This BRM.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BRM.DE Profitability Analysis
1.1 Basic Checks
- BRM had positive earnings in the past year.
- BRM had a positive operating cash flow in the past year.
- Of the past 5 years BRM 4 years were profitable.
- BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BRM's Return On Assets of 7.83% is in line compared to the rest of the industry. BRM outperforms 56.86% of its industry peers.
- With an excellent Return On Equity value of 38.19%, BRM belongs to the best of the industry, outperforming 90.20% of the companies in the same industry.
- The Return On Invested Capital of BRM (19.52%) is better than 76.47% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 17.40%.
- The last Return On Invested Capital (19.52%) for BRM is above the 3 year average (14.47%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROIC | 19.52% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
1.3 Margins
- Looking at the Profit Margin, with a value of 14.64%, BRM is in line with its industry, outperforming 58.82% of the companies in the same industry.
- BRM's Profit Margin has improved in the last couple of years.
- The Operating Margin of BRM (35.82%) is better than 88.24% of its industry peers.
- BRM's Operating Margin has improved in the last couple of years.
- BRM has a Gross Margin (72.63%) which is comparable to the rest of the industry.
- BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. BRM.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
- Compared to 1 year ago, BRM has more shares outstanding
- Compared to 5 years ago, BRM has less shares outstanding
- The debt/assets ratio for BRM has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.52 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
- BRM has a Altman-Z score of 2.52. This is comparable to the rest of the industry: BRM outperforms 45.10% of its industry peers.
- The Debt to FCF ratio of BRM is 3.51, which is a good value as it means it would take BRM, 3.51 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 3.51, BRM is doing good in the industry, outperforming 62.75% of the companies in the same industry.
- A Debt/Equity ratio of 2.33 is on the high side and indicates that BRM has dependencies on debt financing.
- With a Debt to Equity ratio value of 2.33, BRM is not doing good in the industry: 80.39% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Altman-Z | 2.52 |
ROIC/WACC2.3
WACC8.5%
2.3 Liquidity
- BRM has a Current Ratio of 1.26. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of BRM (1.26) is comparable to the rest of the industry.
- BRM has a Quick Ratio of 1.14. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of BRM (1.14) is better than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 |
3. BRM.DE Growth Analysis
3.1 Past
- BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
- Measured over the past years, BRM shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
- The Revenue has decreased by -0.22% in the past year.
- Measured over the past years, BRM shows a small growth in Revenue. The Revenue has been growing by 2.54% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- BRM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.15% yearly.
- Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -5.54% on average per year.
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. BRM.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 9.62, which indicates a very decent valuation of BRM.
- Based on the Price/Earnings ratio, BRM is valued cheaply inside the industry as 90.20% of the companies are valued more expensively.
- BRM's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.91.
- The Price/Forward Earnings ratio is 9.34, which indicates a very decent valuation of BRM.
- 90.20% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of BRM to the average of the S&P500 Index (23.68), we can say BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 9.34 |
4.2 Price Multiples
- 88.24% of the companies in the same industry are more expensive than BRM, based on the Enterprise Value to EBITDA ratio.
- BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 90.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.38 | ||
| EV/EBITDA | 7.25 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRM does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of BRM may justify a higher PE ratio.
- A cheap valuation may be justified as BRM's earnings are expected to decrease with -4.05% in the coming years.
PEG (NY)3.23
PEG (5Y)N/A
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
5. BRM.DE Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 4.30%, BRM is a good candidate for dividend investing.
- BRM's Dividend Yield is rather good when compared to the industry average which is at 1.94. BRM pays more dividend than 82.35% of the companies in the same industry.
- BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.3% |
5.2 History
- On average, the dividend of BRM grows each year by 6.51%, which is quite nice.
Dividend Growth(5Y)6.51%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- BRM pays out 71.52% of its income as dividend. This is not a sustainable payout ratio.
- BRM's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
BRM.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BRM (4/9/2026, 7:00:00 PM)
50.62
+0.43 (+0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners83.3%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap103.09B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target52.4 (3.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.3% |
Yearly Dividend2.18
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)0%
PT rev (3m)11.1%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)0.42%
EPS NY rev (1m)0%
EPS NY rev (3m)4.48%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)6.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 9.34 | ||
| P/S | 2.5 | ||
| P/FCF | 9.38 | ||
| P/OCF | 8.51 | ||
| P/B | 6.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.25 |
EPS(TTM)5.26
EY10.39%
EPS(NY)5.42
Fwd EY10.71%
FCF(TTM)5.4
FCFY10.66%
OCF(TTM)5.95
OCFY11.75%
SpS20.25
BVpS7.76
TBVpS-9.41
PEG (NY)3.23
PEG (5Y)N/A
Graham Number30.31
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROCE | 25.91% | ||
| ROIC | 19.52% | ||
| ROICexc | 23.22% | ||
| ROICexgc | 84.94% | ||
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% | ||
| FCFM | 26.65% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 32.69% | ||
| Cap/Sales | 2.72% | ||
| Interest Coverage | 8.22 | ||
| Cash Conversion | 66.54% | ||
| Profit Quality | 182.1% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.52 |
F-Score7
WACC8.5%
ROIC/WACC2.3
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.75%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%
BRISTOL-MYERS SQUIBB CO / BRM.DE Fundamental Analysis FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for BRM stock?
The Price/Earnings (PE) ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 9.62 and the Price/Book (PB) ratio is 6.52.
Can you provide the financial health for BRM stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.